Biology of Blood and Marrow Transplantation
Volume 15, Issue 1 , Pages 54-60 , January 2009

Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy

  • Carolyn E. Behrendt

      Affiliations

    • Division of Biostatistics and Epidemiology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • Corresponding Author InformationCorrespondence and reprint requests: Carolyn E. Behrendt, PhD, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010.
    • ,
  • Joseph Rosenthal

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • Division of Pediatrics, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • Ellen Bolotin

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • Division of Pediatrics, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • Ryotaro Nakamura

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • John Zaia

      Affiliations

    • Division of Virology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • Stephen J. Forman

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California

Received 11 September 2008 ,Accepted 23 October 2008.

References 

  1. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003–2008
  2. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273–282
  3. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpes viruses. Herpes. 2003;10:12–16
  4. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell depleted stem cell transplantation. Blood. 2000;95:2240–2245
  5. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572–1577
  6. Ljungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075–1081
  7. Ljungman P. Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract Res Clin Haematol. 2007;20:209–217
  8. Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol. 2006;76:414–419
  9. Jacobsen N, Badsberg JH, Lönnqvist B, et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant. 1990;5:413–418
  10. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255–4260
  11. Ringdén O, Schaffer M, Le Blanc K, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biol Blood Marrow Transplant. 2004;10:128–134
  12. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051
  13. Erard V, Guthrie KA, Riddell S, Boeckh M. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2006;91:1377–1383
  14. Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224–1231
  15. Gustafsson Jernberg A, Remberger M, Ringdén O, Winiarski J. Risk factors in pediatric stem cell transplantation for leukemia. Pediatr Transplant. 2004;8:464–474
  16. Bordon V, Bravo S, Van Renterghem L, et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis. 2008;10:19–23
  17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097
  18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  20. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc. 1972;B34:187–220
  21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1140–1154
  22. Klein JP. Modelling competing risks in cancer studies. Stat Med. 2006;25:1015–1034
  23. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics. 2005;61:223–229
  24. Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed. 2008;89:289–300
  25. Matthes-Martin S, Lion T, Aberle SW, et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant. 2003;31:803–808
  26. Paulin T, Ringdén O, Lönnqvist B, Wahren B, Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. Scand J Infect Dis. 1986;18:199–209
  27. Meyers JD, Fluornoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478–488
  28. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332:143–149
  29. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol. 1997;9:339–346
  30. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93:248–256

 Financial disclosure: See Acknowledgments on page 59.

PII: S1083-8791(08)00472-2

doi: 10.1016/j.bbmt.2008.10.023

Biology of Blood and Marrow Transplantation
Volume 15, Issue 1 , Pages 54-60 , January 2009

Article Tools

* Image Usage & Resolution